{'fraction_non_alphanumeric': 0.03015075376884422, 'fraction_numerical': 0.0020100502512562816, 'mean_word_length': 5.264150943396227, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Regulatory effects of human mononuclear cells treated with diucifon may be dependent on membrane-associated form of interleukin-2].

The immunomodulating activity of diucifon--activated and glutaraldehyde fixed human mononuclear cells (MNC-DGA) was studied in the test--system of autologous and allogenic mononuclear cells proliferative response. It was shown that MNC-DGA had the same stimulating activity as the diucifon treated unfixed cells. The immunomodulating capacity of MNC-DGA was fully abolished in the case MNC-DGA. So, the interaction between interleukin 2 receptor (Tac--antigen) and the membrane form of the mediator, expressed on MNC after diucifon treatment may play an important role in MNC-DGA immunomodulating activity. The regulating activity of MNC-DGA was revealed both in autologous and allogenic systems. The speculation is that construction of new immunomodulating drugs as complexes of cell-like carrier and immunomodulators fixed on their surface may be perspective.